Navigation Links
Drug shows promise for the first time against metastatic melanoma of the eye
Date:6/19/2014

NEW YORK, NY (June 19, 2014) For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.

Results from a multicenter clinical trial show that a new drug called selumetinib increases progression-free survival, the length of time during and after treatment that a patient with metastases lives with the disease without it progressing. The findings were published today in the online edition of JAMA, the Journal of the American Medical Association.

"Although the effects of the drug were modest, we now know that we can influence the course of the disease, and we expect to build on this success with other drugs, including some already in development," said senior author, Gary K. Schwartz, MD, professor of medicine and chief of hematology/oncology at NewYork-Presbyterian/Columbia University Medical Center and associate director of its Herbert Irving Comprehensive Cancer Center. (At the time of the trial, Dr. Schwartz was chief of the melanoma and sarcoma service at Memorial Sloan Kettering Cancer Center in New York.)

Uveal melanoma is a cancer of the iris, ciliary body, or choroidstructures in the eye collectively known as the uvea. Uveal melanoma (which is biologically distinct from skin melanoma) arises from the uvea's melanocytes, the pigment cells that give the eye its color. Once the disease has spreadmost metastases appear in the liverexisting treatments are largely ineffective. About 1,500 cases of uveal melanoma occur in the United States each year, usually among older adults. The median survival rate for patients with metastatic uveal melanoma is 12 months.

Several years ago, researchers found that 80 percent of patients with uveal melanoma had mutations to GNAQ or GNA11, genes that activate signals in the mitogen-activated protein kinase (MAPK) pathway. Dr. Schwartz and others subsequently demonstrated that inhibition of M
'/>"/>

Contact: Karin Eskenazi
Ket2116@columbia.edu
Columbia University Medical Center
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. BU-lead study shows surprising spread of spring leaf-out times
2. Study shows race a factor in mortality in heart attack patients on anti-clotting drug
3. Arctic warming linked to fewer European and US cold weather extremes, new study shows
4. New study shows that oatmeal can help you feel full longer
5. Saving trees in tropics could cut emissions by one-fifth, study shows
6. Doing more means changing less when it comes to gene response, new study shows
7. Research shows compassion and euthanasia dont always jibe
8. Study shows impact of tart cherries on inflammation and oxidative stress after cycling
9. Marijuana shows potential in treating autoimmune disease
10. Study shows tale of 2 prognoses in pediatric brain tumor, pilocytic astrocytoma
11. ALK, ROS1 and now NTRK1: Study shows prevalence of new genetic driver in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug shows promise for the first time against metastatic melanoma of the eye
(Date:8/26/2015)... -- The report "Multi-Factor Authentication (MFA) Market by ... & Immigration, Government, Banking, Defense, Commercial Security, Consumer Electronics, ... by MarketsandMarkets, Multi-Factor Authentication Market is expected to reach ... of 17.7% between 2015 and 2020. ... through 169 P ages and in-depth ...
(Date:8/25/2015)... and BELLEVUE, Wash. , Aug. ... advanced robotic systems, announced today it will unveil its ... vehicle (UGV), at the National Tactical Officers Association Conference ... The Guardian S is the first-ever commercially available ... years of research and in-field trials and is protected ...
(Date:8/24/2015)... , August 24, 2015 The ... ,s largest biometrics manufacturer DERMALOG and its customized solutions ... "2015 African Biometrics Company of the Year Award". DERMALOG is ... Nigeria .   -Cross reference: Picture is ... - On Thursday evening, in ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... generation of cancer chemotherapeutic drugs specifically targets mutant enzymes ... uncontrolled cell growth. As promising as these drugs are, ... the tendency to fight back. A major goal of ... desperation. , In a forthcoming issue of Cancer Cell, ...
... Scientists have identified the first biochemical marker linked to sleep ... in activity when sleep deprivation is prolonged. , Researchers hope ... that will aid diagnosis and treatment of sleep disorders and ... at the wheel of a car or in other dangerous ...
... of these epidermal neural crest stem cells in the ... showing that these cells are distinctly different from other ... valuable resource for future mouse neural crest stem cell ... Maya Sieber-Blum's laboratory, co-authored by Yao Fei Hu, Ph.D., ...
Cached Biology News:Distinguishing friend from foe in the battle against cancer 2Distinguishing friend from foe in the battle against cancer 3First biomarker for human sleepiness identified in fruit flies 2First biomarker for human sleepiness identified in fruit flies 3Stem cells found in adult hair follicles may provide alternative to embryonic stem cells 2
(Date:8/25/2015)... (PRWEB) , ... August 25, 2015 , ... ... whether breast tissue lesions are cancerous is described by University of Illinois researchers ... society for optics and photonics. , In “ Breast cancer diagnosis using spatial ...
(Date:8/25/2015)... Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced today ... as Chief Operating Officer. Winham, who brings more than 25 ... report directly to HLI,s CEO, J. Craig Venter , ... Winham will be responsible for managing all HLI sequencing, laboratory ... HLI currently has three locations in San Diego ...
(Date:8/25/2015)... (PRWEB) , ... August 25, ... ... developer of build-to-order, independent blade-based and rackmount computing infrastructure, today announced the ... rackmount offering, the RM1630DX. The latest system boasts two distinct, individually sledded ...
(Date:8/25/2015)... Doximity, the leading medical network for ... its second annual Residency Navigator , an ... of doctors research and compare residency training programs ... senior medical students used Doximity to research the ... The new Residency Navigator brings an unprecedented level ...
Breaking Biology Technology:New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2Cirrascale® Announces Next Generation High Density, Two-in-One GPU Rackmount Offering Perfect for High Performance Remote Workstations 2Cirrascale® Announces Next Generation High Density, Two-in-One GPU Rackmount Offering Perfect for High Performance Remote Workstations 3Doximity Releases 2015-2016 Residency Navigator 2Doximity Releases 2015-2016 Residency Navigator 3
... Growing Generations, the nation,s,largest surrogacy agency, has launched ... to men with HIV and allows them to use,their ... program is made possible due to advances in technology ... the implementation of recent California,legislation enacted in January that ...
... 3 DermTech, a biotechnology,company developing molecular diagnostics ... today announced that Herbert A. Fritsche,Ph.D., has joined ... Chief of Clinical Chemistry at M.D. Anderson Cancer ... development and validation of cancer,diagnostics for early disease ...
... CORAL GABLES, Fla., June 3 Catalyst,Pharmaceutical ... biopharmaceutical company,that acquires, in-licenses, develops and commercializes ... and obsessive compulsive disorders,today announced the filing ... and Exchange Commission (SEC). After the shelf ...
Cached Biology Technology:Growing Generations Announces Surrogacy Program for Men with HIV 2DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Company's Scientific Advisory Board 2Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement 2Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement 3
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Homo sapiens palladin...
Recombinant Rat Leptin, Ultra Pure...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: